Malignant Melanoma Archive - Seite 16 von 19 - IOZK

Larger numbers of immature dendritic cells augment an anti-tumor effect against established murine melanoma cells

2006-12-19/in International Publications, Malignant Melanoma /von 2006-12-19 / Biotechnol. Lett. 2007 Mar;29(3):351-7

Hyperthermia and immunity. A brief overview

2006-11-01/in Hypernephroma, Hyperthermia, International Publications, Malignant Melanoma /von 2006-11-01 / In Vivo 2006 Nov-Dec;20(6A):689-95

Patient-specific dendritic-cell vaccines for metastatic melanoma

2006-09-14/in International Publications, Malignant Melanoma /von 2006-09-14 / N. Engl. J. Med. 2006 Sep;355(11):1179-81

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

2006-09-01/in International Publications, Malignant Melanoma /von 2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-57

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

2006-08-16/in Dendritic Cells, International Publications, Malignant Melanoma /von 2006-08-16 / J Transl Med 2006 Aug;4:36

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients

2006-05-15/in International Publications, Malignant Melanoma /von 2006-05-15 / Int. J. Cancer 2006 May;118(10):2617-27

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

2006-05-05/in International Publications, Malignant Melanoma /von 2006-05-05 / Cancer Gene Ther. 2006 Oct;13(10):905-18

Dendritic cell immunotherapy for melanoma

2006-05-01/in International Publications, Malignant Melanoma /von 2006-05-01 / Rev Recent Clin Trials 2006 May;1(2):87-102

Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses

2006-03-01/in International Publications, Malignant Melanoma /von 2006-03-01 / Int. J. Oncol. 2006 Mar;28(3):585-93

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG

2006-01-17/in International Publications, Malignant Melanoma /von 2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-70